The role of histone demethylases in cancer therapy
- 7 August 2012
- journal article
- review article
- Published by Wiley in Molecular Oncology
- Vol. 6 (6) , 683-703
Abstract
Reversible histone methylation has emerged in the last few years as an important mechanism of epigenetic regulation. Histone methyltransferases and demethylases have been identified as contributing factors in the development of several diseases, especially cancer. Therefore, they have been postulated to be new drug targets with high therapeutic potential. Here, we review histone demethylases with a special focus on their potential role in oncology drug discovery. We present an overview over the different classes of enzymes, their biochemistry, selected data on their role in physiology and already available inhibitors.Keywords
This publication has 146 references indexed in Scilit:
- The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem CellsCancer Cell, 2012
- An Analog of BIX-01294 Selectively Inhibits a Family of Histone H3 Lysine 9 Jumonji DemethylasesJournal of Molecular Biology, 2012
- Role of androgen receptor and associated lysine‐demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancerMolecular Carcinogenesis, 2011
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent DioxygenasesCancer Cell, 2011
- Histone Demethylase JmjD2A Regulates Neural Crest SpecificationDevelopmental Cell, 2010
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- Chromatin Modifications and Their FunctionCell, 2007
- Histone Methylation-Dependent Mechanisms Impose Ligand Dependency for Gene Activation by Nuclear ReceptorsCell, 2007
- Histone H3 Lysine 4 Demethylation Is a Target of Nonselective Antidepressive MedicationsChemistry & Biology, 2006
- Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1Cell, 2004